Format

Send to

Choose Destination
Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23.

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Author information

1
Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland frederic.tissot@chuv.ch.
2
Division of Haemato-Oncology, St Bartholomew's Hospital and Blizard Institute, Queen Mary University, London, UK.
3
Hematology, Catholic University of Sacred Heart, Roma, Italy.
4
School of Medicine, European University Cyprus, Engomi, Cyprus.
5
Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, University Children's Hospital, Münster, Germany.
6
1st Department of Medicine, University of Athens, Greece.
7
Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Austria.
8
Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland.
9
University of Genova (DISSAL), Infectious Disease Division, IRCCS San Martino-IST, Genova, Italy.
10
Oncology and Hematology, Hôpitaux Universitaires de Strasbourg and Université de Strasbourg, France.

Abstract

The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or hematopoietic stem cell transplantation recipients. Meetings are held every two years since 2005 and evidence-based recommendations are elaborated after evaluation of the literature and discussion among specialists of nearly all European countries. In this manuscript, the ECIL group presents the 2015-update of the recommendations for the targeted treatment of invasive candidiasis, aspergillosis and mucormycosis. Current data now allow a very strong recommendation in favor of echinocandins for first-line therapy of candidemia irrespective of the underlying predisposing factors. Anidulafungin has been given the same grading as the other echinocandins for hemato-oncological patients. The beneficial role of catheter removal in candidemia is strengthened. Aspergillus guidelines now recommend the use of either voriconazole or isavuconazole for first-line treatment of invasive aspergillosis, while first-line combination antifungal therapy is not routinely recommended. As only few new data were published since the last ECIL guidelines, no major changes were made to mucormycosis recommendations.

PMID:
28011902
PMCID:
PMC5394968
DOI:
10.3324/haematol.2016.152900
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center